Clinical Scorecard: Addressing the Need for Biologically-Informed Patient Selection in Genitourinary Cancer Treatment Beyond Therapeutic Advances

At a Glance

Key Highlights

• Therapeutic advances include immune checkpoint inhibitors and targeted therapies.
• Current biomarkers are heterogeneous and insufficient for predicting treatment response.
• Tumor biology and microenvironment complexity significantly influence therapeutic outcomes.
• Metabolic reprogramming is a key determinant of tumor progression and treatment sensitivity.
• Future progress requires integrative predictive models combining multi-omics and liquid biopsy approaches.

Guideline-Based Recommendations

Diagnosis

• Utilize tissue-based and circulating biomarkers for prognostic and predictive assessments.

Management

• Adopt precision oncology approaches, including combination therapies and targeted treatments.

Monitoring & Follow-up

• Implement dynamic monitoring of tumor evolution and treatment response.

Risks

• Recognize the limitations of current biomarkers in capturing treatment response.

Patient & Prescribing Data

Patients with various genitourinary malignancies, particularly those with advanced disease.

Combination strategies and precision therapies are essential for optimizing treatment outcomes.

Clinical Best Practices

• Integrate metabolic, immune, and molecular features in treatment decision-making.
• Focus on multidimensional tumor characterization for personalized therapy.

Related Resources & Content

• Ren et al.
• Sharif et al.
• Szeles et al.
• Tang et al.
• Maiorano et al.
• Wang et al.
• Cao et al.
• Song et al.
• Jia et al.
• Zhao et al.
• Li et al.
• Chen et al.
• Benjamin and Hsu